Vikram Sinai Talaulikar: New Perspectives on GLP-1 Therapies for Obesity Management
Vikram Sinai Talaulikar, Associate Specialist in Reproductive Medicine at UCLH and Hon, shared a post on LinkedIn abour a paper by Francesca Celletti et al. published in JAMA:
“The first issue of New Scientist for 2026 brings a sharp focus on to GLP-1 weight loss medications.
It suggests that weight-loss medications should get cheaper and more accessible (with expiry of semaglutide patents in many countries) and the approval of orforglipron which can be taken in a pill form. Also, there are more promising drugs on the horizon that could produce greater benefits (with more than 100 weight-loss drugs in development).
As the article notes, there are still many unanswered questions about long-term effects, what happens when you stop and the access to these agents.
The world health organisation guidelines conclude that medications alone cannot solve the global obesity burden. The availability of GLP-1 therapies should galvanise the global community to build a fair, integrated, and sustainable obesity ecosystem. Countries must ensure equitable access not only to comprehensive disease management, but also to health promotion and prevention policies and interventions targeting the general population and those at high risk.
As health professionals, we are already seeing more of our patients use GLP-1 agents and the numbers are only set to rise in future. We will have to be prepared and informed about what comes next.”
Title: World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults
Authors: Francesca Celletti, Jeremy Farrar, Luz De Regil
Read the full article.
Read more.
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Apr 17, 2026, 18:44Multidisciplinary Guidance Needed for Informed Reproductive Choices – ESHRE
-
Apr 17, 2026, 18:37ART Professionals Invited to Contribute to Updated ESHRE-ALPHA KPI Consensus – ESHRE
-
Apr 17, 2026, 18:31Yannick Hurni: What Is a ‘Normal Uterus’? From Morphology to Function
-
Apr 17, 2026, 18:28Narrative Review Reassesses Luteinizing Hormone Activity in ART – RBMO
-
Apr 17, 2026, 18:20ASRM Celebrates Member Contributions With Sigal Klipstein Spotlight – ASRM
-
Apr 17, 2026, 14:24Rare Cases of Endometriosis in Men – Meliodays Medical
-
Apr 17, 2026, 14:18Hesam Ghafouri Kalajahi: Functional Heterogeneity of Endometriomas in FSH Responsiveness
-
Apr 17, 2026, 14:14Join Us on ASRM/CFAS Business of Medicine Conference 2026 in Chicago – ASRM
-
Apr 17, 2026, 14:12A Call for Reproductive Health Issues to Feature in 2027 Campaign – Collectif BAMP Association